Steve Kean will transition from leading Kinder Morgan to assuming the role of president and CEO of the Greater Houston Partnership later this year. Photo courtesy of the GHP

A longtime energy executive has been named the next president and CEO of the Greater Houston Partnership. He'll take on the new role this fall.

The GHP named Steve Kean, who currently serves as the CEO of Kinder Morgan Inc., to the position. He's expected to transition from CEO to board of directors member at Kinder Morgan on August 1. Kean will then assume his new position at GHP no later than Dec. 1.

Dr. Marc L. Boom, GHP board chair and president and CEO of Houston Methodist, made the announcement at a press conference June 21.

“Steve brings incredible business acumen and leadership skills to the organization," Boom says in a statement. "Coupled with an extraordinary passion for Houston, he will build on the Partnership’s momentum to continue to advance greater Houston as a region of extraordinary growth and opportunity.”

The GHP's outgoing president and CEO, Bob Harvey, announced his retirement earlier this year, and will remain in his position until Kean is onboarded. Kean was selected via a search committee established by 2022 board chair, Thad Hill. The committee was chaired by Marc Watts and included Boom, Thad Hill, Paul Hobby, Gina Luna, Eric Mullins, Armando Perez, and Ruth Simmons. The process, which looked at over 70 highly-qualified Houston leaders, also included the services of Spencer Stuart to manage the search.

“This last decade has been a dynamic time for Houston and the Partnership," Harvey says in a statement. "As a life-long Houstonian, it has been an honor to focus my efforts on supporting Houston’s continued growth and working with the business community to create opportunities for all Houstonians. This is an exciting time for Houston. I am very pleased that Steve is enthusiastic about leading the Partnership, and I look forward to the organization’s continued success under his leadership.”

With decades in the energy industry, Kean joined Kinder Morgan in 2002 and has served as COO, president of Natural Gas Pipelines, and president of Kinder Morgan Inc. before rising to CEO. He received a bachelor's degree from Iowa State University and his law degree from the University of Iowa.

“I’m grateful for the opportunity to serve our region in this role," he says. "I look forward to building on what Bob, the Board, members, and staff of the Partnership have accomplished. I know first-hand the opportunities that a vibrant business sector can create for people and communities. I look forward to expanding those opportunities further.”

Houston Methodist has been recognized in two different awards programs. Courtesy of Methodist Hospital/Facebook

Houston hospital system recognized for patient care and technology

Industry standard

Houston Methodist has a couple new feathers in its cap. The hospital system was recognized with two different awards recently.

Houston Methodist was the only hospital system to have four hospitals receive a 2019 Vizient Bernard A. Birnbaum, M.D., Quality Leadership Award, a recognition that praises hospitals for demonstrating quality and care. The Vizient Quality and Accountability Study has been conducted every year since 2005.

Houston Methodist Hospital was recognized in the in the comprehensive academic medical center category, Houston Methodist Sugar Land received an award in the specialized complex care medical center category, and both Houston Methodist Willowbrook and Houston Methodist The Woodlands were selected for the complex medical center category.

"Having four of our hospitals on this list is extraordinary. Receiving such national recognition is an honor, but I'm most proud that the reason for these awards is our concerted focus on quality patient care," says Marc L. Boom, president and CEO of Houston Methodist, in a news release.

This year was slightly different from years prior, and 349 participating hospitals were divided into four cohorts for the Vizient Quality and Accountability Ranking. Among some of the assets considered were safety, mortality, clinical effectiveness, efficiency and patient centeredness. The announcement was made last week during the 2019 Vizient Connections Education Summit in Las Vegas.

Meanwhile, the hospital system was also recently recognized for being among the "Most Wired" in the United States. For the 12th consecutive year, Houston Methodist received the 2019 HealthCare's Most Wired recognition from the College of Healthcare Information Management Executives, or CHiME. The award recognizes hospital systems for their innovation, adoption, and optimal use of information technology.

New this year was CHiME's ambulatory facilities recognition, which Houston Methodist received for outstanding technical accomplishments, earning a Certified Level 8 Quality Award.

Innovation has an increased focus at Houston Methodist since premiering its Center for Innovation — a group of leaders charged with finding new technologies for the hospital system for patients, physicians, and staff — under the leadership of Roberta Schwartz. She is the system's executive vice president, chief innovation officer, and chief executive officer of Houston Methodist Hospital.

After 17 years at Houston Methodist, Schwartz says she's seen the evolution of tech and is taking note of where the industry is going.

"I think we're an industry that is transforming itself. We're either going to be disrupted or we're going to do the disruption ourselves," Schwartz tells InnovationMap in a previous article. "There's nobody who knows health care better than we do, so if we're going to transform the industry, I want that transformation to come from the inside."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”